Policy & Regulation
Adaptive Phage Therapeutics Names Goodman to its Board of Directors
15 September 2021 - - US-based clinical-stage biotechnology company Adaptive Phage Therapeutics, Inc has appointed Jesse L. Goodman, MD, MPH, to the company's board of directors, the company said.

Dr. Goodman is a Professor of Medicine and Attending Physician, Infectious Diseases, at Georgetown University, where he directs the Center on Medical Product Access, Safety and Stewardship (COMPASS).

Until February 2014 he served as the Chief Scientist of the US Food and Drug Administration, a position he assumed in 2009 along with Deputy Commissioner for Science and Public Health (2009-2012).

From 2003 to 2009, he was director of FDA's Center for Biologics Evaluation and Research, overseeing activities critical to US and global preparedness and the development, evaluation, safety, quality, and availability of blood, vaccines, gene and cell therapies and other biologics.

As Senior Advisor to the FDA Commissioner in 1998-2000, he initiated and, with CDC and NIH colleagues, co-chaired the United States Task Force on Antimicrobial Resistance which produced the nation's first Public Health Action Plan to Combat Antimicrobial Resistance.

Dr. Goodman has previously served on numerous boards and advisory committees for organizations including the CDC, NIH, WHO and the Coalition on Epidemic Preparedness Innovations.

He currently serves on the board (prior president) of the United States Pharmacopeia, as an independent non-executive director for GlaxoSmithKline plc (NYSE: GSK) (chairing its board Science Committee), and is on the board of Intellia Therapeutics, which is developing CRISPR based treatments for human disease.

Dr. Goodman received his degree in biology from Harvard University, earned a master's in public health from the University of Minnesota, and received his M.D. from the Albert Einstein College of Medicine.

He underwent residency and fellowship training in Medicine, Infectious Diseases and Oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles, where he was also Chief Medical Resident.

Prior to his government service at the FDA, he was a Professor of Medicine and Chief of Infectious Diseases at the University of Minnesota.

Adaptive Phage Therapeutics is a clinical-stage company advancing therapies to treat multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been "fixed," while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance increases over time.

APT's PhageBank approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage.

PhageBank phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.

APT's technology was originally developed by the biodefense program of US Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017.

Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.